Charles River has extensive capabilities in fragment-based drug discovery, offering access to expertise in screening, structural biology, and computational and medicinal chemistry.

Our range of fragment libraries and orthogonal fragment screening technologies allows us to customize a fragment-based lead discovery solution to a wide array of target types.

Our fragment-based drug discovery (FBDD) platform provides access to:

Orthogonal Screening TechnologiesTechnologies include thermal shift assay, surface plasmon resonance (SPR) using Biacore™ instrumentation, isothermal titration calorimetry (ITC), NMR, high-concentration biochemical assay and X-ray crystallography
Structural BiologyExperience in the development of structure routes to support FBDD; in-house X-ray facility and Crystal Bank of structures
Fragment Library
1,500 member core library, 500 member kinase focused set and 500 member 19F labelled set, all designed for fragment screening and rapid FBDD optimization of hits
Computational ChemistryProprietary fragment hit expansion techniques and fragment shape-based analysis tools
Medicinal ChemistryExpertise in structure-based drug discovery and fragment hit optimization